News and Trends 20 Mar 2017 French Biotech fails Second Phase II Trial for Cardiovascular Disease Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of… March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Apr 2023 6 biotechs that have stepped into the protein degradation space …even orally. Arvinas’ PROTAC-based pipeline consists of more than 12 drug candidates, which are being studied in immuno-oncological and neuroscience research. Its lead candidate, ARV-471, is an investigative oral protein… April 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2022 Get to know 15 of the best biotech companies in Paris …to modulate the body’s immune system through its immune enhancing and antiviral platforms to treat chronic inflammatory diseases, viral infections and cancer. The company’s lead candidate entered phase 3 trials… November 4, 2022 - 11 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia …discovery of disease targets and the design of small molecule candidates, and Sanofi will take over from preclinical development onwards. Exscientia expects to receive €88M ($100M) upfront in addition to… January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 1 Mar 2024 Tips on how to write a compelling biotech resume As hundreds of resumes make their way to a recruiter’s office, only a handful of the candidates get past an interview. Although acing interviews and networking can boost your chances… March 1, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 12 Oct 2023 Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated? …melanoma, glioblastoma multiforme, castrate-resistant prostate cancer and gastrointestinal stromal tumor. The candidate is designed to target a particular metabolic pathway in the mitochondria. The candidate is presently in phase 1B… October 12, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 Massive €800M Acquisition of Belgian Biotech treating Menopause …candidate targets the tachykinin receptor NK3 in neurons located in the brain. This advantage will certainly give the candidate a strong entrance in the menopausal hot flashes market, which is… April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2018 German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn …to cover two additional TCR candidates. The potential value of the deal thus goes up from $1Bn to $1.5Bn — plus royalties on sales if the candidates make it to… May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding …iTeos, explained to me that both of its immunotherapy candidates target key resistance mechanisms that tumors develop against anti-cancer drugs known as immune checkpoint inhibitors. iTeos’ lead candidate drug does… April 2, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients …candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made the announcement today (November 15)…. November 15, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 AAHI bags $9.9M to develop nasal spray influenza RNA vaccine …develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens…. February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2024 CAR-T cell therapy for lupus: An emerging field with great potential …bring this type of therapy to the market, potentially offering a cure for the disease. So far, though, candidates are still working their way through the clinic trials, and a… December 9, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email